Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rimegepant sulfate ODT by Pfizer for Irritable Bowel Syndrome: Likelihood of Approval
Rimegepant sulfate ODT is under clinical development by Pfizer and currently in Phase II for Irritable Bowel Syndrome. According to...
Palbociclib by Pfizer for Chordoma: Likelihood of Approval
Palbociclib is under clinical development by Pfizer and currently in Phase II for Chordoma. According to GlobalData, Phase II drugs...
Maplirpacept by Pfizer for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Maplirpacept is under clinical development by Pfizer and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Pfizer's Fordadistrogene Movaparvovec?
Fordadistrogene Movaparvovec is a gene therapy commercialized by Pfizer, with a leading Phase III program in Duchenne Muscular Dystrophy. According...
PF-07264660 by Pfizer for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
PF-07264660 is under clinical development by Pfizer and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData,...
Inclacumab by Pfizer for Sickle Cell Disease With Vaso-Occlusive Crisis: Likelihood of Approval
Inclacumab is under clinical development by Pfizer and currently in Phase III for Sickle Cell Disease With Vaso-Occlusive Crisis. According...
Sasanlimab by Pfizer for Solid Tumor: Likelihood of Approval
Sasanlimab is under clinical development by Pfizer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
PF-07799544 by Pfizer for Solid Tumor: Likelihood of Approval
PF-07799544 is under clinical development by Pfizer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
PF-06425090 by Pfizer for Clostridioides difficile Infections (Clostridium difficile Associated Disease): Likelihood of Approval
PF-06425090 is under clinical development by Pfizer and currently in Phase III for Clostridioides difficile Infections (Clostridium difficile Associated Disease)....
PF-07261271 by Pfizer for Inflammatory Bowel Disease: Likelihood of Approval
PF-07261271 is under clinical development by Pfizer and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase...
Sisunatovir hydrochloride by Pfizer for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
Sisunatovir hydrochloride is under clinical development by Pfizer and currently in Phase III for Respiratory Syncytial Virus (RSV) Infections. According...
Bosutinib by Pfizer for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Bosutinib is under clinical development by Pfizer and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...
Binimetinib by Pfizer for Metastatic Colorectal Cancer: Likelihood of Approval
Binimetinib is under clinical development by Pfizer and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
PF-07799544 by Pfizer for Metastatic Melanoma: Likelihood of Approval
PF-07799544 is under clinical development by Pfizer and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Pfizer's Marstacimab?
Marstacimab is a monoclonal antibody commercialized by Pfizer, with a leading Pre-Registration program in Hemophilia B (Factor IX Deficiency). According...
Risk adjusted net present value: What is the current valuation of Pfizer's Inclacumab?
Inclacumab is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease With Vaso-Occlusive...
Risk adjusted net present value: What is the current valuation of Pfizer's Sisunatovir Hydrochloride?
Sisunatovir Hydrochloride is a small molecule commercialized by Pfizer, with a leading Phase III program in Respiratory Syncytial Virus (RSV)...
Risk adjusted net present value: What is the current valuation of Pfizer's PF-06835375?
PF-06835375 is a biologic commercialized by Pfizer, with a leading Phase II program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....
Risk adjusted net present value: What is the current valuation of Pfizer's Giroctocogene fitelparvovec?
Giroctocogene fitelparvovec is a gene therapy commercialized by Pfizer, with a leading Phase III program in Hemophilia A (Factor VIII...
Risk adjusted net present value: What is the current valuation of Pfizer's Maplirpacept?
Maplirpacept is a fusion protein commercialized by Pfizer, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According...